| Pharmaceutical Information |
| Drug Name |
Mepenzolate bromide |
| Drug ID |
BADD_D01383 |
| Description |
Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications. |
| Indications and Usage |
For use as adjunctive therapy in the treatment of peptic ulcer. It has not been
shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.
|
| Marketing Status |
approved |
| ATC Code |
A03AB12 |
| DrugBank ID |
DB04843
|
| KEGG ID |
D00720
|
| MeSH ID |
C005101
|
| PubChem ID |
6461
|
| TTD Drug ID |
D0FV3V
|
| NDC Product Code |
Not Available |
| UNII |
APX8D32IX1
|
| Synonyms |
mepenzolic acid | mepenzolate iodide | mepenzolate bromide | mepenzolic acid, bromine salt | N-methyl-3-piperidylbenzilate methyl bromide | mepenzolate | Cantil | mepenzolate bromide, (+-)-isomer | mepenzolic acid, bromine salt, 1-(methyl-(14)C)-labeled |
|
| Chemical Information |
| Molecular Formula |
C21H26BrNO3 |
| CAS Registry Number |
76-90-4 |
| SMILES |
C[N+]1(CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C.[Br-] |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
